Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExCAVE: Edoxaban for asymptomatic cancer-associated venous thromboembolism in Japanese gastrointestinal cancer patients
jRCTs011180030Completed
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of edoxaban in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE), sponsored by Hokkaido Gastrointestinal Cancer Study Group. Primary endpoint: Incidence of major bleeding and clinically relevant non-major bleeding. Started Oct 2017; status: completed.
02
Drugs
edoxaban
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on jRCTs011180030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011180030.